SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Processing

Read more breaking news

 

 
News in brief

Pall’s Biopharma sales up in Q2

08-Mar-2012
Last updated on 24-Sep-2012 at 14:12 GMT

Filtration and processing tech firm Pall Life Sciences’ biopharmaceutical business made the biggest contribution to its revenues revenues in fiscal Q2.

Total revenue for the three months to January 31 was $357m, up 7 per cent on the comparable quarter in fiscal 2011. Sales to the biopharmaceutical sector rose 12.3 per cent to $201.6m with – according to Pall – growth being seen in its systems, consumables and laboratory businesses.

Larry Kingsley, president and CEO, said: “The sales increase in the quarter reflects good growth in both the Life Sciences and Industrial segments. On a global basis, emerging market sales grew over 20 per cent in local currency driven by the Energy markets in MENA and Latin America.”

Outlook

For the second quarter Pall expects the market to be more challenges – predicting a slowdown in sales and some negative impact from its recent acquisition of analysis instrumentation firm ForteBio .

While we expect some EPS headwind in the second half as sales growth moderates and foreign exchange impacts our consolidated results, we should be able to offset most of the impact with cost and productivity actions underway. The previously announced ForteBio acquisition closed last week. That will be slightly dilutive to our 2012 results.

Key Industry Events

 

Access all events listing

Our events, Events from partners...

Products

Solid Lipid Excipients: Born to be Extruded !
Gattefossé Pharma
USP<233> Elemental Impurities Sample Prep Strategy
SGS Life Science Services
Online Cell Density Monitoring
Hamilton Bonaduz AG
Residual moisture in lyophilized pharmaceuticals
Metrohm – customized analysis for the pharmaceutical industry
Need help to bring insoluble APIs to the market?
Dow Pharma & Food Solutions